血清标志物对慢性乙肝治疗监测价值的研究进展  

The Research Progress on the Monitoring Value of Serum Markers inChronic Hepatitis B Treatment

作　　者：刘婷[1] 戚应杰 LIU Ting;QI Yingjie(Department of Clinical Laboratory,Infection Hospital Area of the First Affiliated Hospital of University of Science andTechnology of China(Anhui Provincial Hospital Infection Hospital),Hefei 230000,China)

机构地区：[1]中国科学技术大学附属第一医院(安徽省立医院)感染病院,安徽合肥230000

出　　处：《标记免疫分析与临床》2023年第11期1972-1976,共5页Labeled Immunoassays and Clinical Medicine

基　　金：深圳市第三人民医院与翰森制药战略合作基金开放性课题-HBVRNA对经治乙肝患者HBeAg转换的预测价值(编号:2022HBV-RNA)。

摘　　要：治疗慢性乙型肝炎的主要药物包括干扰素和核苷(酸)类似物,而慢性乙型肝炎治疗的难点之一是如何确定治疗终点,寻找合适的标志物对疾病进展、药物疗效进行评估是关键。本文回顾和探讨了HBsAg、HBV DNA、HBcrAg、HBV RNA这4种血清标志物在对慢性乙型肝炎治疗监测价值方面的研究进展和各自的局限性。重点阐述了HBV RNA在评估慢性乙型肝炎患者抗病毒治疗疗效和预测慢性乙型肝炎患者抗病毒药物耐药性的产生以及停药后复发方面的价值。The major types of drugs used in the treatment of chronic hepatitis B include interferon and nucleoside(acid)analogues.However,one of the challenges in the treatment of chronic hepatitis B is how to determine the treatment endpoint,in which finding suitable markers to evaluate the disease progression and drug efficacy is the key step.In light of this,the research progress and limitations of four serum markers HBsAg,HBV DNA,HBcrAg and HBV RNA in monitoring the treatment of chronic hepatitis B were reviewed and discussed in the current article.The value of HBV RNA in evaluating the efficacy of antiviral therapy in patients with chronic hepatitis B and predicting the development of antiviral drug resistance and relapse after withdrawal of antiviral drug in patients with chronic hepatitis B was further emphasized.

关 键 词：慢性乙型肝炎 乙型肝炎病毒核心相关抗原 乙型肝炎病毒核糖核酸 

分 类 号：R512.62[医药卫生—内科学]